SCHEMBL10109052

SCHEMBL10109052

COc1ccc(C2=Cc3ccc(OC)cc3[C@@H]3CC(C)(C)CC[C@H]23)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.34
MAPT P10636 1/20 0.34
HSD17B1 P14061 1/20 0.34
RECQL P46063 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HTR2B P41595 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A3 Q01959 2/20 0.33
ADRB2 P07550 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
HTR2C P28335 1/20 0.33
HRH1 P35367 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318139 1.00 LMNA (0.34) LMNAMAPTHSD17B1RECQLSMN1; SMN2
SCHEMBL318134 0.95 LMNA (0.34) LMNAMAPTHSD17B1RECQLSMN1; SMN2
SCHEMBL10109101 0.95 LMNA (0.34) LMNAMAPTHSD17B1RECQLSMN1; SMN2
SCHEMBL317860 0.82 NOS3 (0.44) CYP11B1CYP11B2OPRM1KDM1AMAOA
SCHEMBL317663 0.82 NOS3 (0.47) CYP11B1CYP11B2SIGMAR1OPRM1KDM1A
SCHEMBL10108856 0.82 NOS3 (0.47) CYP11B1CYP11B2SIGMAR1OPRM1KDM1A
SCHEMBL10108826 0.82 NOS3 (0.44) CYP11B1CYP11B2OPRM1KDM1AMAOA
SCHEMBL318392 0.76 CYP11B1 (0.36) MAPTSMN1; SMN2CYP11B1CYP11B2KDM1A
SCHEMBL10108926 0.76 CYP11B1 (0.36) MAPTSMN1; SMN2CYP11B1CYP11B2KDM1A
SCHEMBL10109013 0.71 NOS3 (0.44) CYP11B1CYP11B2OPRM1FDFT1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG LMNA 2755/4885MAPT 224/4885HSD17B1 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.